Latest Articles

Puxitatug Samrotecan Hits 60% Response Rate in Platinum- and IO-Pretreated Endometrial Cancer - Targeted Oncology

Puxitatug Samrotecan Hits 60% Response Rate in Platinum- and IO-Pretreated Endometrial Cancer Targeted Oncology

Data Updates Shift Treatment Standards in Gyn-Oncology - Medscape

Data Updates Shift Treatment Standards in Gyn-Oncology Medscape

Corrigendum to 'Endometriosis and ovarian cancer risk' [Gynecologic Oncology 209C (2026) 88-98].

Dostarlimab/Chemo Shows Curative Potential in dMMR/MSI-H Advanced Endometrial Cancer - Targeted Oncology

Dostarlimab/Chemo Shows Curative Potential in dMMR/MSI-H Advanced Endometrial Cancer Targeted Oncology

Sakar Healthcare, Zydus Lifesciences join hands to expand oncology supply across GCC markets - IndiaMedToday

Sakar Healthcare, Zydus Lifesciences join hands to expand oncology supply across GCC markets IndiaMedToday

Pfizer targets VEGF bispecific white space | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Pfizer targets VEGF bispecific white space | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Sacituzumab Tirumotecan Improves Survival in Advanced Endometrial Cancer - Targeted Oncology

Sacituzumab Tirumotecan Improves Survival in Advanced Endometrial Cancer Targeted Oncology

Adenomyosis Independently Increases Risk for Endometrial Proliferative Disorders - Oncology Nurse Advisor

Adenomyosis Independently Increases Risk for Endometrial Proliferative Disorders Oncology Nurse Advisor

Circulating Tumor DNA in Ovarian Cancer: Emerging Roles in Early Detection, Risk Stratification, and Disease Monitoring.

Early diagnosis of ovarian cancer remains one of the most important unmet needs in gynecologic oncology because survival is strongly stage-dependent and most patients still present with disseminated disease. Conventional …

Five Under 5: Top Oncology Videos for the Week of 4/12 - OncLive

Five Under 5: Top Oncology Videos for the Week of 4/12 OncLive